CDER’s Pharmaceutical Science Office Gets New Director, Probably Its Last
This article was originally published in The Pink Sheet Daily
As Keith Webber departs for Perrigo, Lawrence Yu will step up as Acting Director of the Office of Pharmaceutical Science as FDA prepares to incorporate OPS into soon-to-come Office of Pharmaceutical Quality.
You may also be interested in...
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.
Gregory Geba will step down March 15, saying ongoing organizational changes created challenges to implementing his vision; CDER Director Janet Woodcock will run the office during the nationwide search for a replacement.
More than just a bureaucratic shell game, the promotion of the Office of Generic Drugs to “super office” status signals CDER Director Janet Woodcock’s tightened focus on generic drugs.